IT Services - Germany



hy Hauck Aufhäuser Lamn



Q3 profitability even weaker than expected; chg.

Yesterday, q.beyond released **weak Q3 figures**, showing a slowdown in growth and profitability even below our recently revised estimates as well as significantly below consensus. **In detail**:

Q3 sales increased 5.4% yoy to € 45.5m (eNuW: € 45.1m; eCons: € 46.1m), which was predominantly driven by the accelerated recovery of the SAP segment with 12.3% growth to € 8.8m (eNuW: € 8.7m) following a sales offensive in recent quarters. However, the otherwise strong Cloud & IoT segment showed a significant slowdown in growth with a yoy increase of 3.8% (vs 13.4% in H1; -3% organically, excluding productive data acquisition) to € 36.6m (eNuW: € 36.4m). Besides the general market weakness, the company states price reductions for key customers (e.g. Tchibo) as the main reason for the performance.

Q3 EBITDA decreased 95% yoy to € 0.1m (eNuW: € 0.6m; eCons: € 1.2m), implying a 0.2% margin (-380 bps yoy). Here, especially the reduced segment margin of the Cloud & IoT segment (-130 bps yoy) following inflationary cost increases as well as a substantially lower other operating income of € 0.2m (vs € 1.6m in Q3'22) weighed on profitability.

Despite the weak operating result, management confirmed the FY guidance of € 185-191m sales, € 5-7m EBITDA and FCF of > € -4m. While the sales (eNuW: € 186m; eCons: € 187m; 9M: € 138m) and FCF (eNuW: € 1.4m; eCons: € -2.2m; 9M: € 1.1m) outlook look in reach, the EBITDA target appears more than ambitious in light € -0.1m after 9M and will only be reached thanks to a significant other operating income contribution. This however depends on a decision by the tax authorities concerning the Plusnet sale in 2019, which will, according to management, at least partly turn out in favor of q.beyond leading to the anticipated one-off. Adjusting for this, the EBITDA is seen at € 0.3m (eNuW).

Going forward, especially the increasing near- and off-shore focus, higher utilization rates as well as the *one q.beyond* strategy are seen to have a **positive impact on profitability**. Moreover, the net cash position of € 37.3m should be partly put to work in the form of value accretive M&A in 2024e, leaving a certain upside to our estimates.

Despite shares looking mispriced after the recent weakness and the stock trading at only 0.2x EV/Sales 2023e, there is no catalyst for a possible re-rating in sight, in our view. We confirm **BUY with a PT of € 1.00** based on DCF, while at the same time highlighting the absence of catalysts in the short term.

| Y/E 31.12 (EUR m) | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e |
|--------------------------|--------|--------|--------|-------|-------|--------|
| Sales | 143.4 | 155.2 | 173.0 | 186.1 | 199.1 | 213.5 |
| Sales growth | -39.8% | 8.2% | 11.5% | 7.5% | 7.0% | 7.2% |
| EBITDA | -2.0 | 31.7 | 1.4 | 5.1 | 6.1 | 11.6 |
| Net debt (if net cash=0) | -44.9 | -54.3 | -30.7 | -32.1 | -37.4 | -46.0 |
| FCF | -10.5 | -14.9 | -4.7 | 1.4 | 5.3 | 8.6 |
| Net Debt/EBITDA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EPS pro forma | -0.16 | 0.08 | -0.27 | -0.09 | -0.03 | -0.00 |
| EBITDA margin | -1.4% | 20.5% | 0.8% | 2.7% | 3.1% | 5.4% |
| ROCE | -10.1% | 9.1% | -23.2% | -7.5% | -4.8% | 0.1% |
| EV/sales | 0.2 | 0.1 | 0.3 | 0.2 | 0.2 | 0.1 |
| EV/EBITDA | -16.7 | 0.7 | 31.7 | 8.3 | 6.0 | 2.4 |
| PER | -3.6 | 7.4 | -2.2 | -6.4 | -16.5 | -337.8 |
| Adjusted FCF yield | -37.8% | 136.9% | -23.1% | -0.4% | 13.6% | 33.3% |

Source: Company data, NuWays, Close price as of 13.11.2023



| Market data | |
|-----------------------------|--------|
| Share price (in €) | 0.59 |
| Market cap (in € m) | 71.7 |
| Number of shares (in m pcs) | 124.5 |
| Enterprise value (in € m) | 41.9 |
| Ø trading volume (6 months) | 81,317 |

12m rel. performance

-30.2%

| IUE | enuner |
|-----------|--------------|
| Bloomberg | QBY GR |
| Reuters | QSCGF |
| WKN | 513700 |
| ISIN | DE0005137004 |


| Key snareholders | |
|---------------------|-------|
| Gerd Eickers | 12.7% |
| Dr. Bernd Schlobohm | 12.7% |
| Free Float | 74.7% |


| Estimates changes | | | | | |
|-------------------|-------|--------------|--------------|--|--|
| | 2023e | <u>2024e</u> | <u>2025e</u> | | |
| Sales | 0% | 0% | 0% | | |
| EBIT | -1% | -4% | -30% | | |
| EPS | -1% | -4% | -15% | | |

Comment on changes

- FY23 estimates are slightly adjusted following the Q3 release.
- FY24 & '25 profitability estimates are slightly trimmed as we take a more conservative stance.

Sales (2020-25e) 240.0m 180.0m 120.0m 0.0m 2020 2021 2022 2023e 2024e 2025e Source: NuWays Research





Company description

q.beyond AG is a German-based digital solutions company, active in the fields of cloud management, system applications and products, IoT, and other IT services. The company operates in several countries with a strong focus on the DACH-region.

Guidance

- Sales: € 185-191m
- EBITDA: € 5-7m
- FCF: > € -4m

Preview / Review - 14.11.2023



Financials

| Profit and loss (EUR m) | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e |
|--|---|--|--|---|---|---|
| Sales | 143.4 | 155.2 | 173.0 | 186.1 | 199.1 | 213.5 |
| Sales growth | -39.8% | 8.2% | 11.5% | 7.5% | 7.0% | 7.2% |
| Cost of sales | 120.3 | 124.9 | 145.6 | 157.3 | 163.3 | 170.4 |
| Gross profit | 23.2 | 30.3 | 27.5 | 28.8 | 35.8 | 43.1 |
| Sales and marketing | 12.6 | 12.6 | 12.9 | 13.5 | 14.3 | 14.9 |
| General and administration | 14.7 | 17.2 | 18.7 | 15.6 | 15.9 | 16.5 |
| Research and development | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other operating income | 2.8 | 36.3 | 6.0 | 5.6 | 1.0 | 1.1 |
| Other operating expenses | 0.7 | 5.1 | 0.5 | 0.1 | 0.4 | 1.1 |
| Total operating expenses | 25.1 | -1.5 | 26.1 | 23.7 | 29.7 | 31.5 |
| Unusual or infrequent items | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBITDA | -2.0 | 31.7 | 1.4 | 5.1 | 6.1 | 11.6 |
| Depreciation | 16.8 | 16.6 | 12.3 | 12.7 | 9.5 | 9.4 |
| EBITA | -18.8 | 15.2 | -11.0 | -7.6 | -3.4 | 2.2 |
| Amortisation of goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Amortisation of intangible assets | 0.0 | 0.0 | 21.0 | 2.7 | 2.4 | 2.1 |
| Impairment charges | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBIT (inc revaluation net) | -18.8 | 15.2 | -32.0 | -10.4 | -5.8 | 0.1 |
| Interest income | 0.1 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 |
| Interest expenses | 0.5 | 0.3 | 0.2 | 0.2 | 0.1 | 0.1 |
| Investment income | -0.0 | -0.3 | -0.9 | -0.3 | -0.3 | -0.3 |
| Financial result | -0.5 | -0.5 | -1.0 | -0.3 | -0.4 | -0.4 |
| Recurring pretax income from continuing operations | -19.3 | 14.6 | -32.9 | -10.6 | -6.2 | -0.3 |
| Extraordinary income/loss | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Earnings before taxes | -19.3 | 14.6 | -32.9 | -10.6 | -6.2 | -0.3 |
| Income tax expense | 0.6 | 4.8 | 0.2 | 0.6 | -1.9 | -0.1 |
| Net income from continuing operations | -19.9 | 9.8 | -33.1 | -11.2 | -4.3 | -0.2 |
| Income from discontinued operations (net of tax) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income | -19.9 | 9.8 | -33.1 | -11.2 | -4.3 | -0.2 |
| Minority interest | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net profit (reported) | -19.9 | 9.7 | -33.1 | -11.2 | -4.3 | -0.2 |
| Average number of shares | 124.3 | 124.5 | 124.5 | 124.5 | 124.5 | 124.5 |
| • | | | ^ ^= | 0.00 | 0.00 | 0.00 |
| EPS reported | -0.16 | 0.08 | -0.27 | -0.09 | -0.03 | -0.00 |
| EPS reported | -0.16 | 0.08 | | | | |
| EPS reported Profit and loss (common size) | -0.16 2020 | 0.08 2021 | 2022 | 2023e | 2024e | 2025e |
| Profit and loss (common size) Sales | -0.16 2020 100.0% | 0.08 2021 100.0% | 2022 100.0% | 2023e 100.0% | 2024e 100.0% | 2025e 100.0% |
| Profit and loss (common size) Sales Cost of sales | -0.16 2020 100.0% 83.8% | 0.08 2021 100.0% 80.5% | 2022 100.0% 84.1% | 2023e 100.0% 84.5% | 2024e 100.0% 82.0% | 2025e 100.0% 79.8% |
| EPS reported Profit and loss (common size) Sales Cost of sales Gross profit | -0.16 2020 100.0% 83.8% 16.2% | 0.08 2021 100.0% 80.5% 19.5% | 2022 100.0% 84.1% 15.9% | 2023e 100.0% 84.5% 15.5% | 2024e 100.0% 82.0% 18.0% | 2025e 100.0% 79.8% 20.2% |
| Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing | -0.16 2020 100.0% 83.8% 16.2% 8.8% | 0.08 2021 100.0% 80.5% 19.5% 8.1% | 2022 100.0% 84.1% 15.9% 7.4% | 2023e 100.0% 84.5% 15.5% 7.3% | 2024e 100.0% 82.0% 18.0% 7.2% | 2025e 100.0% 79.8% 20.2% 7.0% |
| EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% |
| EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.0% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.0% |
| EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% |
| Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 0.5% |
| Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 0.5% 14.8% |
| Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses EBITDA | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% -1.4% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 20.5% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.8% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 3.1% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 5.4% |
| Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% -1.4% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 20.5% 10.7% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.8% 7.1% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 5.4% 4.4% |
| EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses EBITDA Depreciation EBITA | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% -1.4% 11.7% -13.1% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 20.5% 10.7% 9.8% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.8% 7.1% -6.3% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 6.8% -4.1% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 3.1% 4.8% -1.7% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 5.4% 4.4% 1.0% |
| Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses EBITDA Depreciation EBITA Amortisation of goodwill | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% -1.4% 11.7% -13.1% 0.0% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 20.5% 10.7% 9.8% 0.0% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.8% 7.1% -6.3% 0.0% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 6.8% -4.1% 0.0% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 3.1% 4.8% -1.7% 0.0% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 5.4% 4.4% 1.0% 0.0% |
| Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses EBITDA Depreciation EBITA Amortisation of goodwill Amortisation of intangible assets | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% -1.4% 11.7% -13.1% 0.0% 0.0% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 20.5% 10.7% 9.8% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.8% 7.1% -6.3% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 6.8% -4.1% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 3.1% 4.8% -1.7% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 5.4% 4.4% 1.0% |
| Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses EBITDA Depreciation EBITA Amortisation of goodwill | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% -1.4% 11.7% -13.1% 0.0% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 10.7% 9.8% 0.0% 0.0% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.8% 7.1% -6.3% 0.0% 12.1% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 6.8% -4.1% 0.0% 1.5% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 3.1% 4.8% -1.7% 0.0% 1.2% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 5.4% 4.4% 1.0% 0.0% 1.0% |
| Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses EBITDA Depreciation EBITA Amortisation of goodwill Amortisation of intangible assets Impairment charges | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% -1.4% 11.7% -13.1% 0.0% 0.0% 0.0% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 10.7% 9.8% 0.0% 0.0% 0.0% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.8% 7.1% -6.3% 0.0% 12.1% 0.0% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 6.8% -4.1% 0.0% 1.5% 0.0% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.5% 0.2% 14.9% 3.1% 4.8% -1.7% 0.0% 1.2% 0.0% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 5.4% 4.4% 1.0% 0.0% 1.0% 0.0% |
| Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses EBITDA Depreciation EBITA Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 17.5% -1.4% 11.7% -13.1% 0.0% 0.0% 0.0% -13.1% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 10.7% 9.8% 0.0% 0.0% 0.0% 9.8% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.8% 7.1% -6.3% 0.0% 12.1% 0.0% -18.5% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 6.8% -4.1% 0.0% 1.5% 0.0% -5.6% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.5% 0.2% 14.9% 3.1% 4.8% -1.7% 0.0% 1.2% 0.0% -2.9% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 5.4% 4.4% 1.0% 0.0% 0.0% 0.0% |
| EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses EBITDA Depreciation EBITA Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% -1.4% 11.7% -13.1% 0.0% 0.0% -13.1% 0.0% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 10.7% 9.8% 0.0% 0.0% 0.0% 0.0% 0.0% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.8% 7.1% -6.3% 0.0% 12.1% 0.0% -18.5% 0.1% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 6.8% -4.1% 0.0% 1.5% 0.0% -5.6% 0.1% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.5% 0.2% 14.9% 3.1% 4.8% -1.7% 0.0% 1.2% 0.0% -2.9% 0.0% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 4.4% 1.0% 0.0% 0.0% 0.0% 0.0% |
| EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses EBITDA Depreciation EBITA Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 17.5% -1.4% 11.7% -13.1% 0.0% 0.0% -13.1% 0.0% 0.3% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 20.5% 10.7% 9.8% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.8% 7.1% -6.3% 0.0% 12.1% 0.0% -18.5% 0.1% 0.1% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 6.8% -4.1% 0.0% 1.5% 0.0% -5.6% 0.1% 0.1% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.5% 0.2% 14.9% 3.1% 4.8% -1.7% 0.0% 1.2% 0.0% -2.9% 0.0% 0.0% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 4.4% 1.0% 0.0% 0.0% 0.0% 0.0% |
| EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses EBITDA Depreciation EBITA Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% -1.4% 11.7% -13.1% 0.0% 0.0% 0.0% -13.1% 0.0% 0.3% -0.0% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 20.5% 10.7% 9.8% 0.0% 0.0% 0.0% 0.0% 0.0% -0.2% -0.2% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.8% 7.1% -6.3% 0.0% 12.1% 0.0% -18.5% 0.1% -0.5% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 6.8% -4.1% 0.0% 1.5% 0.0% -5.6% 0.1% 0.1% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 3.1% 4.8% -1.7% 0.0% 1.2% 0.0% -2.9% 0.0% -0.2% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 4.4% 1.0% 0.0% 0.0% 0.0% 0.0% 0.0% -0.2% |
| Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses EBITDA Depreciation EBITA Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% -1.4% 11.7% -13.1% 0.0% 0.0% 0.0% -13.1% 0.0% 0.3% -0.0% neg. | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 20.5% 10.7% 9.8% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% neg. | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.8% 7.1% -6.3% 0.0% 12.1% 0.0% -18.5% 0.1% 0.1% -0.5% neg. | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 6.8% -4.1% 0.0% 1.5% 0.0% -5.6% 0.1% 0.1% -0.2% neg. | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 3.1% 4.8% -1.7% 0.0% 1.2% 0.0% -2.9% 0.0% -0.2% neg. | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 4.4% 1.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% neg. |
| Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses EBITDA Depreciation EBITA Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% -1.4% 11.7% -13.1% 0.0% 0.0% 0.0% -13.1% 0.0% 0.3% -0.0% neg13.4% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 20.5% 10.7% 9.8% 0.0% 0.0% 0.0% 0.0% 0.2% -0.2% neg. 9.4% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.8% 7.1% -6.3% 0.0% 12.1% 0.0% -18.5% 0.1% 0.1% -0.5% neg19.0% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 6.8% -4.1% 0.0% 1.5% 0.0% -5.6% 0.1% 0.1% -0.2% neg5.7% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 3.1% 4.8% -1.7% 0.0% 1.2% 0.0% -2.9% 0.0% -0.2% neg3.1% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 5.4% 1.0% 0.0% 0.0% 0.0% 0.0% 0.0% -0.2% neg0.1% |
| Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses EBITDA Depreciation EBITA Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% -1.4% 11.7% -13.1% 0.0% 0.0% 0.0% -13.1% 0.0% 0.3% -0.0% neg13.4% 0.0% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 20.5% 10.7% 9.8% 0.0% 0.0% 0.0% 0.0% 0.2% -0.2% neg. 9.4% 0.0% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.8% 7.1% -6.3% 0.0% 12.1% 0.0% -18.5% 0.1% -0.5% neg19.0% 0.0% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 6.8% -4.1% 0.0% 1.5% 0.0% -5.6% 0.1% 0.1% -0.2% neg5.7% 0.0% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 3.1% 4.8% -1.7% 0.0% 1.2% 0.0% -2.9% 0.0% -0.2% neg3.1% 0.0% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 5.4% 1.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0 |
| Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses EBITDA Depreciation EBITA Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% -1.4% 11.7% -13.1% 0.0% 0.0% 0.0% -13.1% 0.0% 0.0% 0.0% -13.4% 0.0% -13.4% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 20.5% 10.7% 9.8% 0.0% 0.0% 0.0% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4% 0.0% 9.4% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.8% 7.1% -6.3% 0.0% 12.1% 0.0% -18.5% 0.1% -0.5% neg19.0% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 6.8% -4.1% 0.0% 1.5% 0.0% -5.6% 0.1% 0.1% -0.2% neg5.7% 0.0% -5.7% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 3.1% 4.8% -1.7% 0.0% 1.2% 0.0% -2.9% 0.0% -2.9% 0.0% -3.1% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 5.4% 1.0% 0.0% 0.0% 0.0% 0.0% 0.0% -0.2% neg0.1% |
| Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses EBITDA Depreciation EBITA Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% -1.4% 11.7% -13.1% 0.0% 0.0% 0.0% -13.1% 0.0% 0.3% -0.0% neg13.4% 0.0% -13.4% -3.2% -13.9% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 20.5% 10.7% 9.8% 0.0% 0.0% 0.0% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4% 0.0% 9.4% 32.7% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.8% 7.1% -6.3% 0.0% 12.1% 0.0% -18.5% 0.1% 0.1% -0.5% neg19.0% -0.5% -19.0% -19.0% -19.1% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 6.8% -4.1% 0.0% 1.5% 0.0% -5.6% 0.1% 0.1% -0.2% neg5.7% 0.0% -5.5% -6.0% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 3.1% 4.8% -1.7% 0.0% 1.2% 0.0% -2.9% 0.0% -0.2% neg3.1% 0.0% -3.1% 30.0% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 5.4% 1.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0 |
| Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses EBITDA Depreciation EBITA Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate Net income from continuing operations | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% -1.4% 11.7% -13.1% 0.0% 0.0% 0.0% -13.1% 0.0% -13.4% 0.0% -13.4% -3.2% -13.9% -13.9% 0.0% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 20.5% 10.7% 9.8% 0.0% 0.0% 0.0% 0.0% 9.4% 0.0% 9.4% 32.7% 6.3% 6.3% 0.1% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.8% 7.1% -6.3% 0.0% 12.1% 0.0% -18.5% 0.1% 0.1% -0.5% neg19.0% -0.5% -19.0% -0.5% -19.1% 0.0% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 6.8% -4.1% 0.0% 1.5% 0.0% -5.6% 0.1% 0.1% -0.2% neg5.7% 0.0% -5.5% -6.0% -6.0% 0.0% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 3.1% 4.8% -1.7% 0.0% 1.2% 0.0% -2.9% 0.0% -2.9% 0.0% -3.1% 30.0% -2.2% -2.2% 0.0% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.0% 0.5% 14.8% 5.4% 4.4% 1.0% 0.0% 0.0% 0.0% 0.0% 0.0% -0.2% neg0.1% 0.0% -0.1% 30.0% -0.1% |
| Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses EBITDA Depreciation EBITA Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate Net income | -0.16 2020 100.0% 83.8% 16.2% 8.8% 10.3% 0.0% 2.0% 0.5% 17.5% -1.4% 11.7% -13.1% 0.0% 0.0% 0.0% -13.1% 0.0% 0.3% -0.0% neg13.4% 0.0% -13.4% -3.2% -13.9% | 0.08 2021 100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% -0.9% 20.5% 10.7% 9.8% 0.0% 0.0% 0.0% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4% 0.0% 9.4% 32.7% 6.3% | 2022 100.0% 84.1% 15.9% 7.4% 10.8% 0.0% 3.5% 0.3% 15.1% 0.8% 7.1% -6.3% 0.0% 12.1% 0.0% -18.5% 0.1% 0.1% -0.5% neg19.0% -0.5% -19.0% -19.0% -19.1% | 2023e 100.0% 84.5% 15.5% 7.3% 8.4% 0.0% 3.0% 0.1% 12.7% 6.8% -4.1% 0.0% 1.5% 0.0% -5.6% 0.1% 0.1% -0.2% neg5.7% 0.0% -5.5% -6.0% | 2024e 100.0% 82.0% 18.0% 7.2% 8.0% 0.0% 0.5% 0.2% 14.9% 3.1% 4.8% -1.7% 0.0% 1.2% 0.0% -2.9% 0.0% -0.2% neg3.1% 30.0% -2.2% -2.2% | 2025e 100.0% 79.8% 20.2% 7.0% 7.8% 0.5% 0.5% 14.8% 5.4% 1.0% 0.0% 0.0% 0.0% 0.0% -0.2% neg0.1% 30.0% -0.1% |

Source: Company data, NuWays

Preview / Review - 14.11.2023



| Balance sheet (EUR m) Intangible assets Property, plant and equipment Financial assets FIXED ASSETS Inventories Accounts receivable | 52.9 49.0 0.2 102.1 0.1 | 51.9 39.0 6.3 97.2 | 28.7 37.8 5.3 | 27.0 27.9 5.3 | 25.6 21.3 | 2025e 24.5 15.1 |
|---|--|------------------------------------|---------------------|---------------------|--------------|-----------------------|
| Financial assets FIXED ASSETS Inventories Accounts receivable | 0.2 102.1 0.1 | 6.3 | 5.3 | | 21.3 | 15.1 |
| Financial assets FIXED ASSETS Inventories Accounts receivable | 102.1 0.1 | | | 53 | | |
| Inventories Accounts receivable | 0.1 | 97.2 | | J.J | 5.3 | 5.3 |
| Inventories Accounts receivable | | | 71.8 | 60.1 | 52.2 | 44.9 |
| | | 0.2 | 0.2 | 0.3 | 0.3 | 0.4 |
| | 37.1 | 35.4 | 39.7 | 40.8 | 43.6 | 46.8 |
| Other assets and short-term financial assets | 3.5 | 5.0 | 4.9 | 4.9 | 4.9 | 4.9 |
| Liquid assets | 44.9 | 56.7 | 36.4 | 35.3 | 40.6 | 49.2 |
| Deferred taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Deferred charges and prepaid expenses | 3.2 | 5.8 | 8.2 | 8.2 | 8.2 | 8.2 |
| CURRENT ASSETS | 88.8 | 103.1 | 89.3 | 89.4 | 97.6 | 109.4 |
| TOTAL ASSETS | 190.9 | 200.3 | 161.1 | 149.6 | 149.8 | 154.2 |
| SHAREHOLDERS EQUITY | 136.6 | 147.1 | 115.1 | 108.1 | 106.5 | 109.1 |
| MINORITY INTEREST | 0.0 | 0.3 | 0.5 | 0.5 | 0.5 | 0.5 |
| Provisions for pensions and similar obligations | 6.3 | 4.8 | 2.3 | 2.3 | 2.3 | 2.3 |
| Other provisions and accrued liabilities | 6.8 | 4.7 | 2.4 | 2.4 | 2.4 | 2.4 |
| Short-term liabilities to banks | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Accounts payable | 22.4 | 25.4 | 24.6 | 24.5 | 26.2 | 28.1 |
| Advance payments received on orders | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other liabilities (incl. from lease and rental contracts) | 17.9 | 13.7 | 7.7 | 7.7 | 7.7 | 7.7 |
| Deferred taxes | 0.3 | 1.6 | 2.2 | 0.3 | 0.3 | 0.3 |
| Deferred income | 0.6 | 0.4 | 0.5 | 0.6 | 0.6 | 0.6 |
| CURRENT LIABILITIES | 40.3 | 39.0 | 32.4 | 32.2 | 33.9 | 35.8 |
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | 190.9 | 200.3 | 161.1 | 149.6 | 149.8 | 154.2 |
| | 100.0 | | | | | |
| Balance sheet (common size) | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e |
| Intangible assets | 27.7% | 25.9% | 17.8% | 18.0% | 17.1% | 15.9% |
| Property, plant and equipment | 25.7% | 19.5% | 23.5% | 18.6% | 14.2% | 9.8% |
| Financial assets | 0.1% | 3.1% | 3.3% | 3.5% | 3.5% | 3.4% |
| FIXED ASSETS | 53.5% | 48.5% | 44.6% | 40.2% | 34.8% | 29.1% |
| Inventories | 0.0% | 0.1% | 0.1% | 0.2% | 0.2% | 0.2% |
| Accounts receivable | 19.4% | 17.7% | 24.6% | 27.3% | 29.1% | 30.3% |
| Other assets and short-term financial assets | 1.8% | 2.5% | 3.0% | 3.2% | 3.2% | 3.2% |
| Liquid assets | 23.5% | 28.3% | 22.6% | 23.6% | 27.1% | 31.9% |
| Deferred taxes | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Deferred charges and prepaid expenses | 1.7% | 2.9% | 5.1% | 5.4% | 5.4% | 5.3% |
| CURRENT ASSETS | 46.5% | 51.5% | 55.4% | 59.8% | 65.2% | 70.9% |
| TOTAL ASSETS | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| SHAREHOLDERS EQUITY | 71.5% | 73.4% | 71.5% | 72.2% | 71.1% | 70.7% |
| MINORITY INTEREST | 0.0% | 0.1% | 0.3% | 0.3% | 0.3% | 0.3% |
| Provisions for pensions and similar obligations | 3.3% | 2.4% | 1.4% | 1.5% | 1.5% | 1.5% |
| Other provisions and accrued liabilities | 3.5% | 2.3% | 1.5% | 1.6% | 1.6% | 1.5% |
| Short-term liabilities to banks | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Accounts payable | 11.8% | 12.7% | 15.3% | 16.4% | 17.5% | 18.2% |
| Advance payments received on orders | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Other liabilities (incl. from lease and rental contracts) | 9.4% | 6.8% | 4.8% | 5.2% | 5.2% | 5.0% |
| Deferred taxes | 0.2% | 0.8% | 1.3% | 0.2% | 0.2% | 0.2% |
| Deferred income | 0.3% | 0.2% | 0.3% | 0.4% | 0.4% | 0.4% |
| CURRENT LIABILITIES | 21.1% | 19.5% | 20.1% | 21.5% | 22.7% | 23.2% |
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |

Source: Company data, NuWays

Preview / Review - 14.11.2023



| Cash flow statement (EUR m) | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e |
|--|--|--|--|--|---|--|
| Net profit/loss | -19.9 | 9.8 | -33.1 | -11.2 | -4.3 | -0.2 |
| Depreciation of fixed assets (incl. leases) | 16.9 | 16.2 | 12.3 | 12.7 | 9.5 | 9.4 |
| Amortisation of goodwill & intangible assets | 0.0 | 0.0 | 21.0 | 2.7 | 2.4 | 2.1 |
| Others | -0.0 | 0.0 | -5.1 | -2.5 | 0.0 | 0.0 |
| Cash flow from operating activities | -13.4 | -12.6 | -11.3 | 0.6 | 5.7 | 9.4 |
| Increase/decrease in inventory | 0.0 | 0.0 | 0.0 | -0.1 | -0.0 | -0.0 |
| Increase/decrease in accounts receivable | -6.3 | 2.4 | -4.3 | -1.1 | -2.9 | -3.1 |
| Increase/decrease in accounts payable | 0.1 | 0.5 | -0.7 | -0.2 | 1.7 | 1.9 |
| Increase/decrease in other working capital positions | 3.2 | -3.5 | 0.6 | 0.0 | 0.0 | 0.0 |
| Increase/decrease in working capital | -2.9 | -0.6 | -4.3 | -1.4 | -1.2 | -1.3 |
| Cash flow from operating activities | -5.0 | -7.7 | -1.3 | 5.2 | 9.2 | 12.8 |
| CAPEX | 5.6 | 7.3 | 3.5 | 3.8 | 4.0 | 4.2 |
| Payments for acquisitions | 1.5 | 15.5 | 10.6 | 0.0 | 0.0 | 0.0 |
| Financial investments | 0.0 | 6.4 | 0.0 | 0.0 | 0.0 | 0.0 |
| Income from asset disposals | 0.0 | 53.8 | 0.1 | 0.0 | 0.0 | 0.0 |
| Cash flow from investing activities | -7.1 | 24.7 | -14.0 | -3.8 | -4.0 | -4.2 |
| Cash flow before financing | -15.8 | 17.0 | -15.2 | 1.4 | 5.3 | 8.6 |
| Increase/decrease in debt position | -5.7 | -5.4 | -0.0 | 0.0 | 0.0 | 0.0 |
| Purchase of own shares | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Capital measures | 0.3 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 |
| Dividends paid | 3.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Others | -0.0 | 0.0 | -5.1 | -2.5 | 0.0 | 0.0 |
| Effects of exchange rate changes on cash | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cash flow from financing activities | -9.1 | -5.3 | -5.1 | -2.5 | 0.0 | 0.0 |
| Increase/decrease in liquid assets | -21.1 | 11.8 | -20.3 | -1.1 | 5.3 | 8.6 |
| Liquid assets at end of period | 44.9 | 56.7 | 36.4 | 35.3 | 40.6 | 49.2 |
| | | | | | | |
| Key ratios (EUR m) | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e |
| P&L growth analysis | | | | | | |
| Sales growth | -39.8% | 8.2% | 11.5% | 7.5% | 7.0% | 7.2% |
| EBITDA growth | -101.4% | -1704.4% | -95.7% | 270.9% | 21.1% | 89.2% |
| EBIT growth | -121.4% | -180.6% | -310.5% | -67.6% | -43.9% | -101.6% |
| EPS growth | -127.0% | -148.7% | -440.7% | -66.1% | -61.3% | -95.1% |
| Efficiency | | | | | | |
| Sales per employee | 144.4 | 152.5 | 148.2 | 155.6 | 164.0 | 170.7 |
| EBITDA per employee | -2.0 | 31.2 | 1.2 | 4.2 | 5.1 | 9.3 |
| No. employees (average) | 994 | 1,018 | 1,167 | 1,196 | 1,214 | 1,250 |
| Balance sheet analysis | | | | | | |
| Avg. working capital / sales | 4.5% | 4.2% | 8.7% | 7.2% | 8.3% | 8.4% |
| Inventory turnover (sales/inventory) | 2,516.1 | 623.1 | 797.3 | 600.0 | 600.0 | 600.0 |
| Accounts receivable turnover | 94.3 | 83.3 | 83.7 | 80.0 | 80.0 | 80.0 |
| Accounts payable turnover | 68.1 | 74.2 | 61.8 | 48.0 | 48.0 | 48.0 |
| Cash flow analysis | | | | | | |
| Free cash flow | -10.5 | -14.9 | -4.7 | 1.4 | 5.3 | 8.6 |
| Free cash flow/sales | -7.4% | -9.6% | -2.7% | 0.8% | 2.6% | 4.0% |
| FCF / net profit | 53.0% | neg. | 14.3% | neg. | neg. | neg. |
| Capex / sales | 3.9% | 8.8% | 2.0% | 2.0% | 2.0% | 2.0% |
| Solvency | | | | | | |
| Net debt | | | | | | |
| | -44.9 | -54.3 | -30.7 | -32.1 | -37.4 | -46.0 |
| Net Debt/EBITDA | -44.9 0.0 | -54.3 0.0 | -30.7 0.0 | -32.1 0.0 | -37.4 0.0 | -46.0 0.0 |
| Net Debt/EBITDA Dividend payout ratio | | | | | | |
| | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Dividend payout ratio | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
| Dividend payout ratio Interest paid / avg. debt | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
| Dividend payout ratio Interest paid / avg. debt Returns | 0.0 0.0% 0.8% | 0.0 0.0% 13.0% | 0.0 0.0% 6.8% | 0.0 0.0% 6.0% | 0.0 0.0% 2.2% | 0.0 0.0% 3.1% |
| Dividend payout ratio Interest paid / avg. debt Returns ROCE ROE | 0.0 0.0% 0.8% | 0.0 0.0% 13.0% 9.1% | 0.0 0.0% 6.8% | 0.0 0.0% 6.0% | 0.0 0.0% 2.2% | 0.0 0.0% 3.1% 0.1% |
| Dividend payout ratio Interest paid / avg. debt Returns ROCE | 0.0 0.0% 0.8% -10.1% -14.6% | 0.0 0.0% 13.0% 9.1% 6.6% | 0.0 0.0% 6.8% -23.2% -28.7% | 0.0 0.0% 6.0% -7.5% -10.4% | 0.0 0.0% 2.2% -4.8% -4.1% | 0.0 0.0% 3.1% 0.1% -0.2% |
| Dividend payout ratio Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield | 0.0 0.0% 0.8% -10.1% -14.6% -37.8% | 0.0 0.0% 13.0% 9.1% 6.6% 136.9% | 0.0 0.0% 6.8% -23.2% -28.7% -23.1% | 0.0 0.0% 6.0% -7.5% -10.4% -0.4% | 0.0 0.0% 2.2% -4.8% -4.1% 13.6% | 0.0 0.0% 3.1% 0.1% -0.2% 33.3% |
| Dividend payout ratio Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS | 0.0 0.0% 0.8% -10.1% -14.6% -37.8% 0.0% | 0.0 0.0% 13.0% 9.1% 6.6% 136.9% 0.0% | 0.0 0.0% 6.8% -23.2% -28.7% -23.1% 0.0% | 0.0 0.0% 6.0% -7.5% -10.4% -0.4% 0.0% | 0.0 0.0% 2.2% -4.8% -4.1% 13.6% 0.0% | 0.0 0.0% 3.1% 0.1% -0.2% 33.3% 0.0% |
| Dividend payout ratio Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield | 0.0 0.0% 0.8% -10.1% -14.6% -37.8% 0.0% 0.0 | 0.0 0.0% 13.0% 9.1% 6.6% 136.9% 0.0% | 0.0 0.0% 6.8% -23.2% -28.7% -23.1% 0.0% 0.0 | 0.0 0.0% 6.0% -7.5% -10.4% -0.4% 0.0% 0.0 | 0.0 0.0% 2.2% -4.8% -4.1% 13.6% 0.0% 0.0 | 0.0 0.0% 3.1% 0.1% -0.2% 33.3% 0.0% 0.0 |
| Dividend payout ratio Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS EPS reported | 0.0 0.0% 0.8% -10.1% -14.6% -37.8% 0.0% 0.0 | 0.0 0.0% 13.0% 9.1% 6.6% 136.9% 0.0% 0.0 | 0.0 0.0% 6.8% -23.2% -28.7% -23.1% 0.0% 0.0 -0.27 | 0.0 0.0% 6.0% -7.5% -10.4% -0.4% 0.0% 0.0 -0.09 | 0.0 0.0% 2.2% -4.8% -4.1% 13.6% 0.0% 0.0 -0.03 | 0.0 0.0% 3.1% 0.1% -0.2% 33.3% 0.0% 0.0 -0.00 |
| Dividend payout ratio Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS EPS reported Average number of shares | 0.0 0.0% 0.8% -10.1% -14.6% -37.8% 0.0% 0.0 | 0.0 0.0% 13.0% 9.1% 6.6% 136.9% 0.0% 0.0 | 0.0 0.0% 6.8% -23.2% -28.7% -23.1% 0.0% 0.0 -0.27 | 0.0 0.0% 6.0% -7.5% -10.4% -0.4% 0.0% 0.0 -0.09 | 0.0 0.0% 2.2% -4.8% -4.1% 13.6% 0.0% 0.0 -0.03 | 0.0 0.0% 3.1% 0.1% -0.2% 33.3% 0.0% 0.0 -0.00 |
| Dividend payout ratio Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS EPS reported Average number of shares Valuation ratios | 0.0 0.0% 0.8% -10.1% -14.6% -37.8% 0.0% 0.0 -0.16 124.3 | 0.0 0.0% 13.0% 9.1% 6.6% 136.9% 0.0% 0.0 0.08 124.5 | 0.0 0.0% 6.8% -23.2% -28.7% -23.1% 0.0% 0.0 -0.27 124.5 | 0.0 0.0% 6.0% -7.5% -10.4% -0.4% 0.0% 0.0 -0.09 124.5 | 0.0 0.0% 2.2% -4.8% -4.1% 13.6% 0.0% 0.0 -0.03 124.5 | 0.0 0.0% 3.1% 0.1% -0.2% 33.3% 0.0% 0.0 -0.00 124.5 |
| Dividend payout ratio Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS EPS reported Average number of shares Valuation ratios P/BV | 0.0 0.0% 0.8% -10.1% -14.6% -37.8% 0.0% 0.0 -0.16 124.3 | 0.0 0.0% 13.0% 9.1% 6.6% 136.9% 0.0% 0.0 0.08 124.5 | 0.0 0.0% 6.8% -23.2% -28.7% -23.1% 0.0% 0.0 -0.27 124.5 | 0.0 0.0% 6.0% -7.5% -10.4% -0.4% 0.0% 0.0 -0.09 124.5 | 0.0 0.0% 2.2% -4.8% -4.1% 13.6% 0.0% 0.0 -0.03 124.5 | 0.0 0.0% 3.1% 0.1% -0.2% 33.3% 0.0% 0.0 -0.00 124.5 |
| Dividend payout ratio Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS EPS reported Average number of shares Valuation ratios P/BV EV/sales | 0.0 0.0% 0.8% -10.1% -14.6% -37.8% 0.0% 0.0 -0.16 124.3 | 0.0 0.0% 13.0% 9.1% 6.6% 136.9% 0.0% 0.08 124.5 | 0.0 0.0% 6.8% -23.2% -28.7% -23.1% 0.0% 0.0 -0.27 124.5 | 0.0 0.0% 6.0% -7.5% -10.4% -0.4% 0.0% 0.0 -0.09 124.5 | 0.0 0.0% 2.2% -4.8% -4.1% 13.6% 0.0% 0.0 -0.03 124.5 | 0.0 0.0% 3.1% 0.1% -0.2% 33.3% 0.0% 0.0 -0.00 124.5 |

Preview / Review - 14.11.2023



Disclosures

Disclosures regarding research publications of NuWays AG pursuant to section 85 of the German Securities Trading Act (WpHG)

Indication of conflict of interest

It is essential that any research recommendation is fairly presented and discloses interests of indicates relevant conflicts of interest. Pursuant to section 85 of the German Securities Trading Act (WpHG) a research report has to point out possible conflicts of interest in connection with the analysed company. A conflict of interest is presumed to exist in particular if NuWays AG

- (1) or any other person belonging to the same group with it was part of a consortium within the past twelve months that issued the financial instruments of the analysed company by way of a public offer.
- (2) or any other person belonging to the same group with it has entered into an agreement on the production of the research report with the analysed company.
- (3) or any other person belonging to the same group with it has been party to an agreement on the provision of investment banking services with the analysed company or have received services or a promise of services under the term of such an agreement within the past twelve month.
- (4) The analysed company holds 5% or more of the share capital of NuWays AG.
- (5) holds (a) a net short position or (b) a net long position of 0.5% of the outstanding share capital of the analysed company.
- (6) or any other person belonging to the same group with it is a market maker or liquidity provider in the financial instruments of the issuer.
- (7) or the analyst has any other significant financial interests relating to the analysed company such as, for example, exercising mandates in the interest of the analysed company.
- (8) The research report has been made available to the analysed company prior to its publication. Thereafter, only factual changes have been made to the report.

Conflicts of interest that existed at the time when this research report was published:

| Company | Disclosures |
|-------------|-------------|
| q.beyond AG | 2 |

| Historical target p | orice and rating changes for o | q.beyond AG | | | |
|---------------------|--------------------------------|--------------------|--------|--------------|----------|
| Company | Date | Analyst | Rating | Target Price | Close |
| q.beyond AG | 02.12.2022 | Sennewald, Philipp | Buy | EUR 1.60 | EUR 0.79 |

Preview / Review - 14.11.2023



1. General Information/Liabilities

This research report has been produced for the information purposes of institutional investors only, and is not in any way a personal recommendation, offer or solicitation to buy or sell the financial instruments mentioned herein. The document is confidential and is made available by NuWays AG exclusively to selected recipients in the European Union (EU) or, in individual cases, also in other countries. It is not allowed to pass the research report on to persons other than the intended recipient without the permission of NuWays AG. Reproduction of this document, in whole or in part, is not permitted without prior permission NuWays AG. All rights reserved.

Under no circumstances shall NuWays AG, any of its employees involved in the preparation, have any liability for possible errors or incompleteness of the information included in this research report – neither in relation to indirect or direct nor consequential damages. Liability for damages arising either directly or as a consequence of the use of information, opinions and estimates is also excluded. Past performance of a financial instrument is not necessarily indicative of future performance.

2. Responsibilities

This research report was prepared by the research analyst named on the front page (the "Producer"). The Producer is solely responsible for the views and estimates expressed in this report. The report has been prepared independently. The content of the research report was not influenced by the issuer of the analysed financial instrument at any time. It may be possible that parts of the research report were handed out to the issuer for information purposes prior to the publication without any major amendments being made thereafter.

3. Organisational Requirements

NuWays AG took internal organisational and regulative precautions to avoid or accordingly disclose possible conflicts of interest in connection with the preparation and distribution of the research report. All members of NuWays AG involved in the preparation of the research report are subject to internal compliance regulations. No part of the Producer's compensation is directly or indirectly related to the preparation of this financial analysis. In case a research analyst or a closely related person is confronted with a conflict of interest, the research analyst is restricted from covering this company.

4. Information Concerning the Methods of Valuation/Update

The determination of the fair value per share, i.e. the price target, and the resultant rating is done on the basis of the adjusted free cash flow (adj. FCF) method and on the basis of the discounted cash flow – DCF model. Furthermore, a peer group comparison is made.

The adj. FCF method is based on the assumption that investors purchase assets only at a price (enterprise value) at which the operating cash flow return after taxes on this investment exceeds their opportunity costs in the form of a hurdle rate of 7.5%. The operating cash flow is calculated as EBITDA less maintenance capex and taxes.

Within the framework of the DCF approach, the future free cash flows are calculated initially on the basis of a fictitious capital structure of 100% equity, i.e. interest and repayments on debt capital are not factored in initially. The adjust-

ment towards the actual capital structure is done by discounting the calculated free cash flows with the weighted average cost of capital (WACC), which takes into account both the cost of equity capital and the cost of debt. After discounting, the calculated total enterprise value is reduced by the interest-bearing debt capital in order to arrive at the equity value.

NuWays AG uses the following three-step rating system for the analysed com-

Buy: Sustainable upside potential of more than 20% within 12 months

Sell: Sustainable downside potential of more than 20% within 12 months.

Hold: Upside/downside potential is limited. No immediate catalyst visible.

The decision on the choice of the financial instruments analysed in this document was solely made by NuWays AG. The opinions and estimates in this research report are subject to change without notice. It is within the discretion of NuWays AG whether and when it publishes an update to this research report, but in general updates are created on a regular basis, after 6 months at the latest. A sensitivity analysis is included and published in company's initial studies.

5. Major Sources of Information

Part of the information required for this research report was made available by the issuer of the financial instrument. Furthermore, this report is based on publicly available sources (such as, for example, Bloomberg, Reuters, VWD-Trader and the relevant daily press) believed to be reliable. NuWays AG has checked the information for plausibility but not for accuracy or completeness.

6. Competent Supervisory Authority

NuWays AG is an affiliated company of Hauck Aufhäuser Lampe Privatbank AG which is under supervision of the BaFin – German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Straße 24 – 28, 60439 Frankfurt a.M.

7. Specific Comments for Recipients Outside of Germany

This research report is subject to the law of the Federal Republic of Germany and the European Union (EU). The distribution of this information to other states in particular to the USA, Canada, Australia and Japan may be restricted or prohibited by the laws applicable within this state. If this communication is distributed in the United Kingdom it is solely directed at (i) investment professionals as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO") or (ii) high net-worth entities as defined in article 49 of the FPO. This document should not be distributed or forwarded, either directly or indirectly, to any other individuals.

8. Miscellaneous

According to Article 4(1) No. i of the delegated regulation 2016/958 supplementing regulation 596/2014 of the European Parliament, further information regarding investment recommendations of the last 12 months are published under: www.nuways-ag.com

Date of publication creation: 14/11/2023 07:50 AM

Date of publication dissemination: 14/11/2023 07:50 AM

Preview / Review - 14.11.2023



Contacts

NuWays AG

Mittelweg 16-17 20148 Hamburg Germany +49 170 119 8648 info@nuways-ag.com www.nuways-ag.com



Christian Sandherr Co-CEO/Analyst

christian.sandherr@nuways-ag.com



Frederik Jarchow Co-CEO/Analyst

frederik.jarchow@nuways-ag.com



Philipp Sennewald

Analyst

philipp.sennewald@nuways-ag.com



Henry Wendisch

Analyst

henry.wendisch@nuways-ag.com



Mark Schüssler

Analyst

mark-hendrik.schuessler@nuways-ag.com



Konstantin Völk

Analyst

konstantin.voelk@nuways-ag.com

Find us on Social Media

<u>Instagram</u>



Twitter/X



LinkedIn

